- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Squamous cell carcinoma of the head and neck (SCCHN)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1981KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 576KB)
Pembrolizumab – November 2020
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
19 March 2021